GoldenGolden
Advanced Search
Haya Therapeutics

Haya Therapeutics

A pre-clinical biopharmaceutical company that is utilizing data from RNA to treat heart failure. It was founded in 2019 and is located in Lausanne, Switzerland.

Haya Therapeutics is a Switzerland-based company that is researching RNA-therapeutics, specifically on long noncoding RNA.It is in the pre-clinical stages of its research and testing. It has the stated goal of being the first company to translate its research on long noncoding RNA to treat to heart failure.

Product

The company is researching the RNA molecule that causes the scarring which leads to heart failure. It utilizes the knowledge of Wisper (Wisp2 super-enhancer-associated RNA) to treat the underlying causes of heart failure. It is developing a method to inject a modified DNA molecule that would affect the Wisper. Haya Therapeutics is testing its research on animals with the stated intention of eventually testing and treating humans. As of 2019, the test results have been successful in preventing the development of heart failure in animal testing.

Funding

The company is funded by several investors, such as Venture Kick and Start Lab.It has had four funding rounds: two grants, one seed, and one debt financing round.

Timeline

2019
Haya Therapeutics was founded.

Funding rounds

People

Name
Role
LinkedIn

Daniel Blessing, PhD

CTO and Co-Founder

Samir Ounzain, PhD

CEO and Co-Founder

Thierry Pedrazzini, PhD

Chair of the Scientific Advisory Board

& Co-Founder

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

HAYA Therapeutics 2019 Venture winner

July 8, 2019

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
FinSMEs
May 21, 2021
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
Mark Zipkin
May 20, 2021
BioSpace
Two different companies, cardiac fibrosis RNA company HAYA Therapeutics and COVID-19 bispecific player RenBio, launched today with funding rounds designed to push them toward the clinic.
Kyle LaHucik
May 19, 2021
FierceBiotech
Haya Therapeutics, a Swiss precision medicine biotech, came out of stealth today with nearly $20 million in seed funding for anti-fibrotic therapies targeting emerging field of long non-coding RNAs

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.